675 related articles for article (PubMed ID: 25774903)
21. Endothelial Sphingosine-1-Phosphate Receptor 4 Regulates Blood-Brain Barrier Permeability and Promotes a Homeostatic Endothelial Phenotype.
Hansen L; Lohfink N; Vutukuri R; Kestner RI; Trautmann S; Hecht M; Wagner PV; Spitzer D; Khel MI; Macas J; Ferreirós N; Gurke R; Günther S; Pfeilschifter W; Devraj K
J Neurosci; 2022 Mar; 42(10):1908-1929. PubMed ID: 34903569
[TBL] [Abstract][Full Text] [Related]
22. Sera from neuromyelitis optica patients disrupt the blood-brain barrier.
Shimizu F; Sano Y; Takahashi T; Haruki H; Saito K; Koga M; Kanda T
J Neurol Neurosurg Psychiatry; 2012 Mar; 83(3):288-97. PubMed ID: 22100760
[TBL] [Abstract][Full Text] [Related]
23. [Fingolimod treatment in multiple sclerosis].
Tanaka M
Nihon Rinsho; 2014 Nov; 72(11):2010-4. PubMed ID: 25518386
[TBL] [Abstract][Full Text] [Related]
24. Fingolimod for relapsing multiple sclerosis: an update.
Horga A; Castilló J; Montalban X
Expert Opin Pharmacother; 2010 May; 11(7):1183-96. PubMed ID: 20367536
[TBL] [Abstract][Full Text] [Related]
25. Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
Chiba K; Adachi K
Future Med Chem; 2012 Apr; 4(6):771-81. PubMed ID: 22530640
[TBL] [Abstract][Full Text] [Related]
26. [Sphingosine-1-phosphate signaling system and the innovative mechanism of action of fingolimod in treatment of multiple sclerosis: review of foreign literature].
Shmyrev VI; Kryzhanovskiĭ SM; Danilycheva IV
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(2 Pt 2):93-7. PubMed ID: 22677684
[TBL] [Abstract][Full Text] [Related]
27. Accelerated differentiation of human induced pluripotent stem cells to blood-brain barrier endothelial cells.
Hollmann EK; Bailey AK; Potharazu AV; Neely MD; Bowman AB; Lippmann ES
Fluids Barriers CNS; 2017 Apr; 14(1):9. PubMed ID: 28407791
[TBL] [Abstract][Full Text] [Related]
28. Soluble VCAM-1 impairs human brain endothelial barrier integrity via integrin α-4-transduced outside-in signalling.
Haarmann A; Nowak E; Deiß A; van der Pol S; Monoranu CM; Kooij G; Müller N; van der Valk P; Stoll G; de Vries HE; Berberich-Siebelt F; Buttmann M
Acta Neuropathol; 2015 May; 129(5):639-52. PubMed ID: 25814153
[TBL] [Abstract][Full Text] [Related]
29. Novel oxazolo-oxazole derivatives of FTY720 reduce endothelial cell permeability, immune cell chemotaxis and symptoms of experimental autoimmune encephalomyelitis in mice.
Imeri F; Fallegger D; Zivkovic A; Schwalm S; Enzmann G; Blankenbach K; Meyer zu Heringdorf D; Homann T; Kleuser B; Pfeilschifter J; Engelhardt B; Stark H; Huwiler A
Neuropharmacology; 2014 Oct; 85():314-27. PubMed ID: 24863045
[TBL] [Abstract][Full Text] [Related]
30. A human pluripotent stem cell-derived in vitro model of the blood-brain barrier in cerebral malaria.
Gopinadhan A; Hughes JM; Conroy AL; John CC; Canfield SG; Datta D
Fluids Barriers CNS; 2024 May; 21(1):38. PubMed ID: 38693577
[TBL] [Abstract][Full Text] [Related]
31. Central effects of fingolimod.
Cruz VT; Fonseca J
Rev Neurol; 2014 Aug; 59(3):121-8. PubMed ID: 25030072
[TBL] [Abstract][Full Text] [Related]
32. Impact of sphingosine 1-phosphate modulation on immune outcomes.
Pinschewer DD; Brinkmann V; Merkler D
Neurology; 2011 Feb; 76(8 Suppl 3):S15-9. PubMed ID: 21339486
[TBL] [Abstract][Full Text] [Related]
33. Targeting intracerebral inflammation in multiple sclerosis: is it feasible?
Lassmann H
Acta Neuropathol; 2012 Sep; 124(3):395-6. PubMed ID: 22797580
[No Abstract] [Full Text] [Related]
34. Serum amyloid A-induced blood-brain barrier dysfunction associated with decreased claudin-5 expression in rat brain endothelial cells and its inhibition by high-density lipoprotein in vitro.
Matsumoto J; Dohgu S; Takata F; Iwao T; Kimura I; Tomohiro M; Aono K; Kataoka Y; Yamauchi A
Neurosci Lett; 2020 Nov; 738():135352. PubMed ID: 32931862
[TBL] [Abstract][Full Text] [Related]
35. Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications.
Camm J; Hla T; Bakshi R; Brinkmann V
Am Heart J; 2014 Nov; 168(5):632-44. PubMed ID: 25440790
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic interference with leukocyte recirculation in multiple sclerosis.
Sellebjerg F; Sørensen PS
Eur J Neurol; 2015 Mar; 22(3):434-42. PubMed ID: 25582213
[TBL] [Abstract][Full Text] [Related]
37. Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.
Strader CR; Pearce CJ; Oberlies NH
J Nat Prod; 2011 Apr; 74(4):900-7. PubMed ID: 21456524
[TBL] [Abstract][Full Text] [Related]
38. Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration.
Massberg S; von Andrian UH
N Engl J Med; 2006 Sep; 355(11):1088-91. PubMed ID: 16971715
[No Abstract] [Full Text] [Related]
39. Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations.
Miyazaki Y; Niino M; Fukazawa T; Takahashi E; Nonaka T; Amino I; Tashiro J; Minami N; Fujiki N; Doi S; Kikuchi S
Clin Immunol; 2014 Apr; 151(2):127-35. PubMed ID: 24607506
[TBL] [Abstract][Full Text] [Related]
40. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology.
Brinkmann V
Pharmacol Ther; 2007 Jul; 115(1):84-105. PubMed ID: 17561264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
